Lipid Nanoparticles (LNP) Industry Promoted by COVID-19

LNPs are liposome-like structures specifically designed to encapsulate a variety of nucleic acids (RNA and DNA). As such, they are the most popular non-viral gene delivery systems. Exelead develops and manufactures LNPs that encapsulate different types of gene payloads, including siRNA, mRNA and saRNA.

LNPs are mainly composed of cationic lipids and other lipid components. These typically include neutral phospholipid molecules belonging to the phosphatidylcholine (PC) class and sterols such as cholesterol. Another common lipid component is known as a PEGylated phospholipid, which is a polyethylene glycol (PEG) polymer covalently attached to the phospholipid head group. Solid lipid nanoparticles (SLN, sLNP) or lipid nanoparticles (LNP) are nanoparticles composed of lipids. They are new drug delivery systems (and part of nanoparticle drug delivery) and new drug formulations. LNP as a drug delivery vehicle was first approved in 2018 with the siRNA drug Onpattro. LNP became more pronounced in late 2020 when some COVID-19 vaccines using RNA vaccine technology coated fragile mRNA chains with PEGylated lipid nanoparticles as delivery vehicles (Lipoid and Pfizer including both BioNTech COVID-19 vaccines).

Market competition is fierce with high-tech barriers. Merck KGaA, Exelead, Avanti Polar Lipids, Nippon Fine Chemical and Genevant Sciences are industry leaders with high-end customers. The top five manufacturers accounted for he 76.24% of the market in 2020 lipid nanoparticles (LNP) sales.

The global size of lipid nanoparticles (LNPs) is estimated to be USD 829.68 million in 2026 from USD 104.25 million in 2020, a change of 459.44% from 2020 to 2021. The global market size of lipid nanoparticles (LNPs) will grow at a CAGR of 7.3% over the next five years.

Leave a Reply